CA
NZ
UK
AU
IND
US
…
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops RXC008, a gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the RAS-RAF-MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
| Income before tax | -17.80M | -21.44M | -9.17M | -6.33M | -10.15M |
| Net income | -18.00M | -21.58M | -9.21M | -4.32M | -8.85M |
| Selling general administrative | 10.23M | 6.46M | 0.05M | 0.05M | 0.22M |
| Gross profit | 18.69M | 10.04M | 5.68M | 2.78M | 0.13M |
| Reconciled depreciation | 0.89M | 0.63M | 0.67M | 0.09M | 0.16M |
| Ebit | -16.27M | -19.75M | -8.27M | -7.19M | -10.14M |
| Ebitda | -15.19M | -19.10M | -7.60M | -7.09M | -9.98M |
| Depreciation and amortization | 1.07M | 0.65M | 0.67M | 0.10M | 0.16M |
| Operating income | -16.27M | -19.75M | -8.27M | -7.19M | -9.20M |
| Other operating expenses | 37.25M | 29.78M | 13.96M | 10.32M | 9.33M |
| Interest expense | 1.73M | 1.71M | 0.97M | 0.10M | 0.00M |
| Tax provision | 0.20M | 0.13M | 0.04M | -2.02M | -1.30M |
| Interest income | 0.19M | 0.01M | 0.01M | 0.01M | 0.02M |
| Net interest income | -1.54M | -1.70M | -0.97M | -0.09M | 0.02M |
| Income tax expense | 0.20M | 0.13M | 0.04M | -2.02M | -1.30M |
| Total revenue | 18.69M | 10.04M | 5.68M | 3.13M | 0.13M |
| Total operating expenses | 37.25M | 29.78M | 13.96M | 9.97M | 9.33M |
| Cost of revenue | - | - | 0.00M | 0.35M | 9.24M |
| Total other income expense net | -1.54M | -1.70M | -0.89M | 0.86M | -0.95M |
| Net income from continuing ops | -18.00M | -21.58M | -9.21M | -4.32M | -8.85M |
| Net income applicable to common shares | -18.00M | -21.58M | -9.21M | -4.32M | -8.85M |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 25.64M | 62.48M | 39.55M | 33.59M | 6.36M |
| Intangible assets | - | 0.09M | 0.10M | 0.10M | 0.11M |
| Other current assets | - | 5.52M | 6.26M | 1.96M | 2.10M |
| Total liab | 22.28M | 29.16M | 26.41M | 30.90M | 4.87M |
| Total stockholder equity | 3.35M | 33.32M | 13.13M | 2.69M | 1.49M |
| Other current liab | 0.84M | 4.89M | 4.32M | 7.07M | 0.95M |
| Common stock | 3.35M | 3.35M | 2.75M | 1.95M | 1.26M |
| Capital stock | 3.35M | 3.35M | 2.75M | 1.95M | 1.26M |
| Retained earnings | -113.83M | -81.31M | -64.23M | -42.21M | -34.14M |
| Good will | - | 0.31M | 0.31M | 0.31M | 0.31M |
| Cash | 18.09M | 53.85M | 29.55M | 27.51M | 3.70M |
| Total current liabilities | 21.01M | 27.20M | 9.59M | 10.93M | 4.87M |
| Net debt | -0.41M | -35.55M | -12.16M | -7.04M | -3.24M |
| Short term debt | 16.41M | 16.35M | 0.57M | 0.50M | 0.47M |
| Short long term debt | 15.73M | 15.73M | - | 0.00M | 0.47M |
| Short long term debt total | 17.68M | 18.30M | 17.40M | 20.47M | 0.47M |
| Other stockholder equity | 113.83M | 111.28M | 74.61M | 42.95M | 34.37M |
| Property plant equipment | - | 2.70M | 3.33M | 3.71M | 0.13M |
| Total current assets | 23.30M | 59.38M | 35.81M | 29.47M | 5.81M |
| Net tangible assets | - | 32.92M | 12.73M | 2.28M | 1.07M |
| Net receivables | 5.21M | 5.50M | 6.26M | 0.84M | 1.43M |
| Long term debt | - | 0.00M | 14.25M | 16.76M | - |
| Accounts payable | 3.76M | 5.96M | 4.70M | 3.36M | 3.44M |
| Accumulated other comprehensive income | - | - | - | -1.79M | -1.14M |
| Common stock total equity | - | - | - | 1.95M | 1.26M |
| Non currrent assets other | - | - | 0.41M | - | 0.55M |
| Non current assets total | 2.33M | 3.10M | 3.73M | 4.12M | 0.55M |
| Capital lease obligations | 1.95M | 2.57M | 3.15M | 3.71M | - |
| Breakdown | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
| Investments | -0.24M | -0.75M | -0.06M | 0.03M | -0.11M |
| Change to liabilities | -5.59M | -1.41M | 7.33M | -0.71M | -8.96M |
| Total cashflows from investing activities | -0.24M | -0.75M | -0.06M | 0.03M | -0.11M |
| Net borrowings | -0.82M | -0.79M | 22.89M | 1.00M | 1.00M |
| Total cash from financing activities | 32.98M | 24.14M | 23.47M | 1.87M | -0.05M |
| Net income | -18.00M | -21.58M | -9.21M | -4.32M | -8.85M |
| Change in cash | 24.30M | 2.04M | 23.81M | -2.77M | -17.34M |
| Begin period cash flow | 29.55M | 27.51M | 3.70M | 6.47M | 23.81M |
| End period cash flow | 53.85M | 29.55M | 27.51M | 3.70M | 6.47M |
| Total cash from operating activities | -8.47M | -21.38M | 0.40M | -4.67M | -17.18M |
| Issuance of capital stock | 34.57M | 25.98M | 2.10M | - | 0.00M |
| Depreciation | 0.89M | 0.63M | 0.67M | 0.09M | 0.16M |
| Other cashflows from investing activities | - | - | 0.00M | 0.06M | 0.02M |
| Change to account receivables | 7.63M | -4.65M | -0.91M | 0.45M | 0.57M |
| Sale purchase of stock | - | 25.98M | 2.10M | - | - |
| Other cashflows from financing activities | -1.59M | -1.84M | 26.37M | 1.87M | -0.05M |
| Change to netincome | 6.61M | 5.63M | 2.52M | -0.18M | -0.10M |
| Capital expenditures | 0.26M | 0.75M | 0.06M | 0.03M | 0.13M |
| Change in working capital | 2.04M | -6.07M | 6.42M | -0.27M | -8.39M |
| Stock based compensation | 4.37M | 3.79M | 0.57M | 0.04M | - |
| Other non cash items | 2.25M | 1.70M | 0.96M | -0.93M | -0.39M |
| Free cash flow | -8.73M | -22.13M | 0.34M | -4.70M | -17.31M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GNS Genus PLC |
18.00 0.78% |
2340.00 | 36.08 | 26.18 | 2.53 | 3.46 | 2.92 | 15.38 |
| ONT Oxford Nanopore Technologies Ltd |
10.60 4.93% |
225.60 | - | - | 4.71 | 2.50 | 4.23 | -8.89 |
| OXB Oxford BioMedica PLC |
5.00 0.95% |
532.00 | - | 208.33 | 4.05 | 7.60 | 4.42 | 308.96 |
| AVCT Avacta Group PLC |
-1.00 1.60% |
61.50 | - | - | 2849.46 | 1929.84 | 2525.51 | -12.04 |
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops RXC008, a gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the RAS-RAF-MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.
| Name | Title | Year Born |
|---|---|---|
| Ms. Lisa Mary Whewell Anson | CEO & Exec. Director | 1970 |
| Dr. James Mead | Chief Operating Officer | 1978 |
| Mr. Peter J. Collum | Chief Financial Officer | NA |
| Dr. Richard Armer | Chief Scientific Officer | NA |
| Dr. Karl Hard Ph.D. | Head of Investor Relations | 1962 |
| Ms. Claire Solk | Gen. Counsel & Company Sec. | NA |
| Ms. Caitlin Pearson | Head of Communications | NA |
| Dr. Jane Robertson | Chief Medical Officer | NA |
| Dr. Cliff Jones | Sr. VP of Chemistry, DMPK & Intellectual Property | NA |
| Dr. Caroline Phillips | Sr. VP of Biology | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.26%
Communication Services
-0.18%
Consumer Cyclical
-0.36%
Consumer Defensive
+0.07%
Energy
-0.01%
Financial Services
-0.26%
Financials
-2.20%
Healthcare
-0.55%
Industrials
-0.08%
Real Estate
-0.33%
Technology
-0.70%
Utilities
-0.41%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...